10-K: Scientific Industries Narrows Loss, Boosts Bioprocessing Focus

Scientific Industries, Inc. reported a significantly reduced net loss for fiscal year 2025, driven by the sale of its Genie product line and continued investment in its Bioprocessing Systems segment.

Summary

• Scientific Industries, Inc. (SI) is engaged in the design, manufacture, and marketing of standard benchtop laboratory equipment and bioprocessing systems.
• The company sold its Genie product line on August 7, 2025, for $9.6 million, plus an earn-out of up to $1.5 million ($1.14 million guaranteed), resulting in a gain of $5,263,400.
• Net loss for the year ended December 31, 2025, was $1,220,400, a substantial improvement from $6,445,400 in 2024.
• Loss from continuing operations decreased to $1,780,300 in 2025 from $8,023,600 in 2024.
• Net revenues increased by 5.4% to $5,053,800 in 2025 from $4,797,100 in 2024, primarily due to increased sales in the Torbal division (Benchtop Laboratory Equipment), offset by decreased Bioprocessing Systems sales.
• Gross profit percentage decreased to 25.8% in 2025 from 41.8% in 2024, mainly due to $757,400 in inventory write-offs within the Bioprocessing segment; without these, it would have been 42.6%.
• The company continues to invest significantly in its Bioprocessing Systems Operations for future revenue generation and expects material R&D expenditures in fiscal year 2026.
• A private placement on April 18, 2025, raised $1,550,000 through the sale of common stock and warrants.
• An accumulated deficit of $35,150,900 was reported as of December 31, 2025, and the company expects continued negative cash flows from operations in the foreseeable future.
• Management believes current cash and proceeds from the Genie sale are sufficient to fund operations for at least one year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, primarily due to the significant reduction in net loss and the strategic capital infusion from the Genie product line sale, which provides a runway for continued investment in the high-growth bioprocessing sector. However, ongoing operating losses, declining gross profit percentage (due to write-offs), and the early stage of the bioprocessing segment temper the overall sentiment.

Positives

• Net loss significantly reduced to $1,220,400 in 2025 from $6,445,400 in 2024.
• Loss from continuing operations decreased substantially to $1,780,300 in 2025 from $8,023,600 in 2024.
• Net revenues increased by 5.4% to $5,053,800 in 2025, driven by the Benchtop Laboratory Equipment Operations.
• The sale of the Genie product line generated a gain of $5,263,400 and provided significant cash flow.
• Cost savings initiatives led to decreases in general and administrative expenses ($850,600 reduction), selling expenses ($60,800 reduction), and research and development expenses ($410,200 reduction).
• Cash and cash equivalents increased by $367,100 to $955,000 as of December 31, 2025.
• Management believes current cash and proceeds from the Genie sale are sufficient to fund operations for at least one year.
• Successful introduction of a major new VIVID product in February 2025, with plans for continued investment.
• The 'One Big Beautiful Bill Act' (OBBBA) enacted on July 4, 2025, permits immediate expensing of domestic R&D expenditures and deduction of previously capitalized amounts, which the company is eligible to apply.

Negatives

• Gross profit percentage decreased to 25.8% in 2025 from 41.8% in 2024, primarily due to $757,400 in inventory write-offs within the Bioprocessing segment.
• The Bioprocessing Systems segment experienced decreased sales in 2025.
• The remaining Torbal division (Benchtop Laboratory Equipment) is not yet profitable after the Genie sale.
• The company continues to incur substantial corporate costs.
• Accumulated deficit of $35,150,900 as of December 31, 2025.
• Expects to continue generating negative cash flows from operations in the foreseeable future.
• The company has a history of operating losses and expects future losses during the next few years as it attempts to grow the bioprocessing sector.
• An impairment loss of $291,000 was recognized for intangible assets within the Bioprocessing segment in 2025.
• Sales to one customer (VIVID Pill counter) represented 31% of consolidated net revenues and 42% of Benchtop Laboratory Equipment sales in 2025, indicating customer concentration risk.
• Purchases from one vendor represented 15.2% of consolidated net purchases in 2025, indicating vendor concentration risk.
• The company is a small participant in its industries with larger competitors.
• Bioprocessing products are complex and have taken longer to develop than anticipated.
• Foreign sales decreased to 17% of net revenue in 2025 from 23% in 2024.

Risks

• Limited financial resources and the potential need to raise additional funding, which may not be available on acceptable terms or at all.
• Raising additional capital through equity sales may cause dilution to existing shareholders and introduce unfavorable terms.
• Debt financing, if available, may result in fixed payment obligations and restrictive covenants that limit business operations.
• Securing financing could divert substantial time and attention from management, adversely affecting day-to-day activities.
• Raising funds through collaborations or divestitures may require relinquishing valuable rights to technologies or future revenue streams.
• A history of operating losses and the likelihood of incurring future losses during the growth and development of the bioprocessing sector.
• Failure to maintain proper and effective internal controls over financial reporting could impair the ability to produce accurate and timely financial statements.
• A limited public market for common stock on the Over-the-Counter Bulletin Board, leading to high volatility and potential difficulty in selling shares or raising capital.
• The commercial success of bioprocessing products largely depends on attaining significant market acceptance, which is uncertain in a new, rapidly innovating market.
• Inability to obtain and maintain patent and other intellectual property protection for new bioprocessing products could allow competitors to develop similar products.
• If trademarks and trade names are not adequately protected, the company may not be able to build name recognition and compete effectively.
• Loss of key management personnel (Helena Santos, Zachary Rovinsky, Karl Nowosielski, Daniel Donadille, John A. Moore) could seriously harm the ability to execute business strategy.
• Inability to retain, fully utilize, or hire additional qualified personnel, especially in the bioprocessing sector, due to intense competition.
• Future success depends heavily on international operations, particularly the Bioprocessing Systems Operations in Germany, which poses risks related to internal controls and differing laws.
• Failure to successfully manage any experienced growth could place significant strain on management and resources.
• Growth strategy is based on assumptions about the bioprocessing market that may prove incorrect, impacting projected sales and addressable market size.
• Dependence on a major customer for 31% of consolidated net revenues and 42% of Benchtop Laboratory Equipment sales in 2025, posing a risk of material reduction in sales.
• The company is a small participant in its industries, facing significant competition from substantially larger competitors with greater resources.
• The ability to grow and compete effectively depends on developing and marketing new products, with bioprocessing products being complex and taking longer to develop than anticipated.
• Exposure to foreign exchange rate risk (transactional and translational) due to the Aquila acquisition and operations in Germany.
• Vulnerability to general economic, political, and social factors, including budgetary constraints affecting customer funding for research activities.
• Higher material and transportation costs and tariffs could negatively impact future gross margins if cost increases cannot be passed on to customers.
• Heavy dependence on outside suppliers for components, including single-source suppliers and foreign factories, leading to long lead times and potential shortages.
• Limited patent protection for Benchtop Laboratory Equipment products, other than the VIVID pill counter, making other products vulnerable to competition.
• Cybersecurity threats, including operational disruption, intellectual property theft, fraud, harm to stakeholders, legal risks, and reputational damage.

Future Outlook

The company expects to continue investing substantial capital in its bioprocessing sector and anticipates material research and development expenditures in fiscal year 2026. It also plans additional product launches for its VIVID product line. While the company expects continued negative cash flows from operations in the foreseeable future, it believes current cash and proceeds from the Genie division sale are sufficient to fund operations for at least one year. However, there is no assurance that management's current operating plan will be successful, and the company may need to decrease expenses, materially increase revenues, or secure additional external capital to continue as a going concern.

Management Comments

• "We expect to continue to incur operating losses for the foreseeable future as our expenses related to the growth and expansion of our Bioprocessing Systems operations will exceed revenues expected to be generated."
• "The Company expects that research and development expenditures in the fiscal year ending December 31, 2026 will continue to be material reflecting continued product development efforts for the Bioprocessing Systems operations."
• "Based on managements current operating plan, the Company believes its cash on hand, including its investments, are sufficient to fund the Company's operations for a period of at least one year subsequent to the issuance of the accompanying consolidated financial statements."
• "However, there is no assurance that management's current operating plan will be successful."

Industry Context

StockSavvy.ai notes that Scientific Industries' strategic pivot towards bioprocessing systems aligns with a broader industry trend of increasing investment in life sciences and biotechnology, particularly in areas requiring advanced sensor technology and software analytics for research and development. The sale of the mature Genie product line, while providing immediate capital and reducing losses, highlights the company's commitment to this higher-growth, albeit more capital-intensive, segment. The challenges in achieving market acceptance and profitability in bioprocessing, as noted in the filing, are common for smaller players entering a market dominated by larger, established competitors like Sartorius AG and Eppendorf SE. The company's reliance on in-house product development and external consultants for specialized engineering reflects a common strategy for smaller firms to innovate without the overhead of large R&D departments.

Comparison to Industry Standards

• The bioprocessing market is characterized by rapid innovation and is dominated by larger players such as Sartorius AG (Germany) and Eppendorf SE (Germany), which offer total solutions. Scientific Industries, with its focus on smart sensors and software analytics (e.g., CGQ, LIS, MPS), is a smaller participant in the laboratory-scale sector.
• Direct competitors for Scientific Industries' bioprocessing products include ABER Instruments (United Kingdom) and PreSens GmbH (Germany), which also specialize in monitoring and sensor technologies.
• In the benchtop laboratory equipment market, Scientific Industries' Torbal brand competes with established companies like Ohaus Corporation (American), A&D Company Ltd. (Japanese), and Adam Equipment Co., Ltd. (British). For VIVID automated pill counters, competitors include Capsa Healthcare (American) and Medility Inc. (Korean). These competitors generally possess greater financial, production, and marketing resources.
• The company's gross profit percentage of 25.8% (or 42.6% excluding write-offs) for 2025 is lower than typical for established, profitable specialty equipment manufacturers, which often see gross margins in the 45-60% range, reflecting the challenges of its start-up bioprocessing segment and inventory issues.
• The significant accumulated deficit of $35.15 million and ongoing operating losses are indicative of a company in a heavy investment phase, particularly for its bioprocessing segment, which is still in its "start-up stage," contrasting with the profitability profiles of mature industry leaders.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any pending legal proceedings as of December 31, 2025.

Related Party Transactions

• John Nicols, a Director, provides consulting services to the Bioprocessing System segment under an agreement that renews automatically each year. For the years ended December 31, 2025 and 2024, the company paid annual fees of $96,000. He was also issued 35,000 stock options in September 2023, valued at $114,700.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity financings; increased value from reduced net loss and strategic asset sale; continued risk from operating losses and thin trading market.
• Employees: Continued investment in Bioprocessing Systems may create new opportunities; cost savings initiatives could impact some roles; stock options and compensation plans are in place.
• Customers: Continued availability of Torbal products; new VIVID product introductions; potential for advanced bioprocessing solutions.
• Suppliers: Dependence on a few single-source suppliers and overseas factories creates supply chain risk.
• Creditors: Improved liquidity from asset sale and capital raise may reduce immediate credit risk, but ongoing operating losses and future funding needs remain a concern.

Next Steps

• Continue to invest significantly in the product development of Bioprocessing Systems Operations.
• Continue to invest in the VIVID product line, with additional launches planned for the near future.
• Research and development expenditures in fiscal year 2026 are expected to continue to be material.
• The company will need to decrease expenses or materially increase revenues, and/or secure additional external capital resources to continue as a going concern.
• The company is currently evaluating ASU 2025-05 and ASU 2025-11 to determine their impact on consolidated financial statements.
• The company is evaluating the impact of adopting ASU 2024-03 on its disclosures.

Key Dates

Recommendation

The company has made significant strides in reducing its net loss and improving liquidity through the strategic sale of its Genie product line. This provides a much-needed capital injection to fund its pivot towards the higher-growth bioprocessing sector. However, the bioprocessing segment is still in its "start-up stage," incurring substantial R&D and operating losses, and faces significant market acceptance and competitive risks. The decline in gross profit percentage due to inventory write-offs and continued negative cash flow from operations indicate that profitability remains a distant goal. While the long-term potential of bioprocessing is attractive, the company's small market position, customer concentration, and ongoing need for external capital suggest a "hold" recommendation. Investors should monitor the progress of the bioprocessing segment's revenue generation and path to profitability, as well as the company's ability to secure future funding without excessive dilution.

Keywords

Scientific Industries, Bioprocessing Systems, Benchtop Laboratory Equipment, SEC 10-K, Annual Report, Genie product line sale, Net loss reduction, Revenue growth, Inventory write-offs, Equity financing, Warrants, Stock options, Corporate governance, Risk factors, Intellectual property, Market acceptance, Customer concentration, Supplier dependence, Foreign exchange risk, R&D expenditures, Sarbanes-Oxley Act, Internal controls, OTC Market, SCND